Search results
FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness'
FierceBiotech· 7 hours agoThe FDA has slammed the brakes on MediLink Therapeutics’ trial of a BioNTech-partnered antibody-drug...
Lilly’s Phase II results in Alzheimer’s disease have most experts saying donanemab is done
Clinical Trials Arena via Yahoo Finance· 14 hours agoEli Lilly’s donanemab for early symptomatic Alzheimer’s disease (AD) has most experts dubious of the...
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias...
FOX40 Sacramento· 4 days agoStarting from molecular design, the unique approach of α bias with β and γ attenuated were...
100 Ways To Make Money Without a Job
GOBankingRates via Yahoo Finance· 5 days agoIf you want to make money outside of a 9-to-5 job, then you should take a look at these 100 ways to score some income without having a traditional job.
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple
Investor's Business Daily· 5 days agoRevenue from Eli Lilly's weight-loss drug is expected to triple over the next five years to over $50...
MDs' One-Word Summary of Long COVID Progress: 'Frustration'
Medscape· 7 days agoStuart Malcolm, MD, a primary care physician who practices in Oregon and northern California,...
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
FierceBiotech· 3 days agoGilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially...
Izokibep Marches on for Psoriatic Arthritis
MedPage Today· 2 days agoAfter 16 weeks of treatment in the randomized, placebo-controlled study, 40% and 43% of patients receiving 160 mg of izokibep weekly or biweekly,...
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater...
Morningstar· 5 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory...
Morningstar· 4 days agoPfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed ...
